<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653377</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0144</org_study_id>
    <secondary_id>2018-A01314-51</secondary_id>
    <nct_id>NCT03653377</nct_id>
  </id_info>
  <brief_title>Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)</brief_title>
  <official_title>Survey on the Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis Followed in Cystic Fibrosis (CF) Center in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background The main risk factor for cervical cancer is the infection by human papillomavirus&#xD;
      (HPV). Vaccination against HPV, offered to all girls aged 11 to 14 is an effective method of&#xD;
      prevention against cervical pathology. Despite this, vaccination coverage against HPV remains&#xD;
      low in France. A proportion of women with cystic fibrosis may be involved in transplantation,&#xD;
      a factor associated with a higher risk of HPV carriage and cervical pathology. An over-risk&#xD;
      of cervical pathology would also be present in women with non-transplanted cystic fibrosis.&#xD;
      Particular attention to vaccination should therefore be included in this population.&#xD;
&#xD;
      Objectives of the study The main objective of the study is to estimate the frequency of HPV&#xD;
      vaccination in young girls with CF over 9 years and followed in a pediatric CF center.&#xD;
&#xD;
      The secondary objectives are to know:&#xD;
&#xD;
        -  The type of vaccine used (bivalent / quadrivalent / nonavalent)&#xD;
&#xD;
        -  The proportion of vaccinated girls with respect of the vaccination schedule (number of&#xD;
           injections / spacing between doses)&#xD;
&#xD;
        -  Reasons for non-use of vaccination&#xD;
&#xD;
      Study design The study will last 12 months. It is a cross-sectional, non-interventional,&#xD;
      multicenter conducted by self-administered questionnaire.&#xD;
&#xD;
      Population&#xD;
&#xD;
        -  young girls aged 9 years or older with Cystic fibrosis&#xD;
&#xD;
        -  Followed in a pediatric or mixed CF center in the France (Rhone-Alpes Auvergne Region&#xD;
           and Ile de France Region)&#xD;
&#xD;
        -  With parents who did not object to participation in the study&#xD;
&#xD;
      Number of subject: 62 patients&#xD;
&#xD;
      Expected results&#xD;
&#xD;
        -  Knowledge of HPV vaccination coverage in young girls with CF.&#xD;
&#xD;
        -  Sensitization of patients, their parents and health professionals to HPV vaccination.&#xD;
           Understand the barriers and reasons for refusing vaccination to promote actions to&#xD;
           improve immunization coverage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HPV vaccination</measure>
    <time_frame>Baseline</time_frame>
    <description>The outcome measure is having HPV vaccination. This information is collected through a self-questionnaire, completed by the patients or their parents, during a visit to the CF center</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">81</enrollment>
  <condition>Mucoviscidosis</condition>
  <arm_group>
    <arm_group_label>Patients with self-administered questionnaire</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self administrated questionnaire</intervention_name>
    <description>Questionnaires are distributed to patients with their parents during their visit to the CF center.</description>
    <arm_group_label>Patients with self-administered questionnaire</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of minor girls with cystic fibrosis older than 9 years, followed in a pediatric&#xD;
        Mucoviscidosis Resource and Competence Center (MRCC).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  young girls aged 9 years or older&#xD;
&#xD;
          -  patients with Cystic Fibrosis&#xD;
&#xD;
          -  patients followed in a pediatric or mixed CF center in the France (Rhone-Alpes&#xD;
             Auvergne Region and Ile de France Region)&#xD;
&#xD;
          -  patients with parents who did not object to participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -patients who refuse to answer to the self-administrated questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine ROUSSET-JABLONSKI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service Mucoviscidose, Pneumologie</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle Couple / Enfant</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRCM, Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRCM, Hôpital Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRCM, Institut Necker Enfants Malade</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Ressources et de Compétences de la Mucoviscidose Adultes</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mucoviscidosis</keyword>
  <keyword>Human Papilloma Virus</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Young girl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

